Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway

Rasha Abu-Eid, Raed N. Samara, Laurent Ozbun, Maher Y. Abdalla, Jay A. Berzofsky, Kevin M. Friedman, Mikayel Mkrtichyan and Samir N. Khleif
Rasha Abu-Eid
1Georgia Regents University Cancer Center, Augusta, Georgia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raed N. Samara
2National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Ozbun
2National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maher Y. Abdalla
2National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jay A. Berzofsky
2National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin M. Friedman
3bluebird bio, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikayel Mkrtichyan
1Georgia Regents University Cancer Center, Augusta, Georgia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samir N. Khleif
1Georgia Regents University Cancer Center, Augusta, Georgia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: SKhleif@gru.edu
DOI: 10.1158/2326-6066.CIR-14-0095 Published November 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    The inhibition of PI3K and Akt in human T cells selectively inhibits the proliferation of human Tregs compared with Tconvs in a dose-dependent manner. Tregs (CD4+CD25HI) and Tconvs (CD4+CD25−) were fractionated from human PBMCs by cell sorting. Proliferation was examined by dilution of CFSE after stimulation with anti-CD3/anti-CD28 for 3 days with titrated amounts of triciribine (TCN), MK-2206, wortmannin (WM), and IC87114. Dead cells were excluded by 7-AAD incorporation. Left, average of three experiments, normalized to untreated controls; right, representative examples. A, a significant reduction in Treg proliferation was observed in response to Akt inhibition by triciribine compared with that of Tconvs at all doses tested: 5 μmol/L (P = 0.04), 10 μmol/L (P = 0.03), and 50 μmol/L (P = 0.01). B, a significant reduction of Treg proliferation in response to MK-2206 treatment was observed compared with that of Tconvs at the 1 μmol/L (P = 0.05) and 5 μmol/L (P = 0.005) doses. C, proliferation of Tregs was significantly reduced by wortmannin compared with that of Tconvs at all doses tested: 300 nmol/L (P = 0.03), 800 nmol/L (P = 0.01), and 1,000 nmol/L (P = 0.002). D, Treg proliferation was significantly reduced by IC87114 compared with that of Tconvs at the 10 μmol/L (P = 0.04) and 20 μmol/L (P < 0.005) doses. *, P < 0.05.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    PI3K and Akt inhibition differentially inhibits the proliferation and downstream activation of murine Tregs compared with that of Tconvs. Mouse CD4+ splenocytes were fractionated into CD25+ (Treg) and CD25− (Tconv) subsets using magnetic bead enrichment kits. Proliferation was assayed by the dilution of CFSE after stimulation with anti-CD3/anti-CD28 for 3 days with wortmannin (WM; 200 nmol/L), MK-2206 (2 μmol/L), IC87114 (10 μmol/L), or DMSO. Dead cells were excluded by 7-AAD incorporation. A, representative example of the selective proliferation inhibition in Tregs (bottom) by wortmannin, MK-2206, and IC87114 compared with that of Tconvs (top). B, treatment with wortmannin, triciribine (TCN), IC87114, or MK-2206 resulted in a marked decrease of phosphorylated S6 in Tregs (CD25+) in comparison with Tconvs (CD25−). C, densitometry of phosphorylated S6 levels to S6 ratio showed significantly lower levels in Tregs when compared with Tconvs when the stimulated cells were treated with PI3K–Akt pathway inhibitors. Densitometry was performed on gel as shown in B.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. Mice were conditioned with wortmannin (WM; 40 μg), triciribine (TCN; 50 μg), MK-2206 (10 μg), or DMSO for 1 week on alternate days before flow cytometric analysis of splenocytes. Alternatively, mice were conditioned on alternate days with either wortmannin or DMSO for a week before vaccination with E7. One week after E7 vaccination, splenocytes were harvested, and the E7 immune response was assayed by ELISPOT. A, mice treated with DMSO vehicle contained similar percentages of CD4 T cells compared with wortmannin-, triciribine-, or MK-2206–treated animals (P = 0.1). B, the number of FoxP3+ cells in CD4+ T cells was significantly reduced in the mice treated with the inhibitors compared with DMSO (P < 0.05). C, vaccination resulted in a significant increase in E7-reactive T cells. Wortmannin and triciribine treatment significantly increased the number of E7-reactive cells compared with DMSO-treated controls. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    PI3K–Akt signaling inhibition mitigates tumor growth. A, TC-1 tumor-bearing mice were treated with wortmannin (WM) or DMSO for 1 week after palpable tumors were detected. Mice were then vaccinated with E7 peptide and tumor growth was monitored. Both E7 vaccination (P < 0.05) and wortmannin treatment (P < 0.001) significantly inhibited TC-1 tumor growth, yet the greatest impairment was achieved with the combination of wortmannin treatment and E7 vaccination (P < 0.0001). B, mice were prophylactically treated with wortmannin, triciribine (TCN), or DMSO before s.c. B16 tumor inoculation and tumor growth was monitored. Tumor growth was significantly inhibited by wortmannin and triciribine compared with DMSO-treated animals (P < 0.0001). **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Akt inhibition by MK-2206 enhances the antitumor therapeutic effect of tumor-specific vaccine. TC-1 tumor-bearing mice were injected on days 7 and 14 with the E7 vaccine and/or MK-2206 (30 μg). The tumors were measured and the mice euthanized on day 21. A, the combination of MK-2206 with the vaccine had a synergistic effect in the reduction of tumor volume in comparison with the vaccine alone (P < 0.05; combined data from two independent experiments). B, the combination of MK-2206 with the vaccine significantly increased the number of tumor-infiltrating CD8+ T cells in comparison with the nontreated control (P < 0.001; representative example). C, the combination of MK-2206 with the vaccine significantly reduced the number of tumor-infiltrating CD4+Foxp3+ Tregs in comparison with the vaccine alone (P < 0.05; representative example). *, P < 0.05; **, P < 0.01; ***, P < 0.001.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    PI3K–Akt inhibition reduces tumor growth in a Treg-dependent manner. Mice were prophylactically treated with wortmannin (WM), triciribine (TCN), or DMSO before s.c. CT26 tumor inoculation. Ex vivo–cultured Tregs were infused in wortmannin-treated mice on day 4 after tumor inoculation. Tumor growth was monitored and the Foxp3+ T-cell infiltrate was then assessed on days 20 and 24. A, prophylactic treatment of the mice with triciribine for 1 week before s.c. tumor inoculation resulted in a significant tumor growth inhibition (P < 0.0001). B, prophylactic treatment of the mice with wortmannin for 1 week before s.c. tumor inoculation resulted in a significant tumor growth inhibition wortmannin (P < 0.0001). This effect was reversed when Tregs were reconstituted by ex vivo–cultured Treg infusion on day 4. C, analysis of FoxP3+ T-cell infiltration into CT26 tumor (days 20 and 24) elucidated a significant decrease in Treg numbers per million tumor cells after wortmannin treatment (P < 0.01), which was restored after the infusion of ex vivo–grown Tregs. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

PreviousNext
Back to top
Cancer Immunology Research: 2 (11)
November 2014
Volume 2, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
Rasha Abu-Eid, Raed N. Samara, Laurent Ozbun, Maher Y. Abdalla, Jay A. Berzofsky, Kevin M. Friedman, Mikayel Mkrtichyan and Samir N. Khleif
Cancer Immunol Res November 1 2014 (2) (11) 1080-1089; DOI: 10.1158/2326-6066.CIR-14-0095

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
Rasha Abu-Eid, Raed N. Samara, Laurent Ozbun, Maher Y. Abdalla, Jay A. Berzofsky, Kevin M. Friedman, Mikayel Mkrtichyan and Samir N. Khleif
Cancer Immunol Res November 1 2014 (2) (11) 1080-1089; DOI: 10.1158/2326-6066.CIR-14-0095
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Nutlin-3a: An Immune-Checkpoint Activator for NK Cells in Neuroblastoma
  • Therapy to Engage, Expand, and Enable Antitumor Responses
  • Dietary Fructose Promotes Resistance to Cancer Immunotherapy
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement